Sign In
Last checked at 
11 Mar 2025 15:25
SMITH & NEPHEW PLC
11 March 2025
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020
On 11 March 2025, the Company received notification of the following transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.
i. VESTING OF 2022 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 20 May 2022, and vested on 9 March 2025 at 59.3% of target for PDMRs who were members of the Company's Executive Committee on the date of grant, and 78.1% for other PDMRs appointed to the Executive Committee subsequent to the date of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Vesting of Smith & Nephew Global Share Plan 2020: Performance Share Programme awards granted on 20 May 2022, and subsequent sale of shares to cover tax liability |
Date of Transaction | 9 March 2025 (vesting) and 10 March 2025 (market sale) |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information |
Helen Barraclough (Group General Counsel and Company Secretary) | PDMR | 11.441599
| 18,951 (of which 8,939 were sold and 10,012 retained) | N/A Single Transaction |
Paul Connolly (President Global Operations) | PDMR | 11.441599
| 23,831 (of which 8,143 were sold and 15,688 retained) | N/A Single Transaction |
Phil Cowdy (Chief Corporate Development and Corporate Affairs Officer) | PDMR | 11.441599
| 20,420 (of which 9,632 were sold and 10,788 retained) | N/A Single Transaction |
Craig Gaffin (President, Global Orthopaedics) | PDMR | 11.441599
| 10,859 (of which 3,232 were sold and 7,627 retained) | N/A Single Transaction |
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) | PDMR | 11.441599
| 24,368 (of which 9,009 were sold and 15,359 retained) | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | 11.441599
| 29,821 (of which 11,866 were sold and 17,955 retained) | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development ENT) | PDMR | 11.441599
| 29,009 (of which 10,772 were sold and 18,237 retained) | N/A Single Transaction |
Alison Parkes (Chief Compliance Officer)
| PDMR | 11.441599
| 7,010 (of which 2,854 were sold and 4,156 retained) | N/A Single Transaction |
Scott Schaffner (President Sports Medicine) | PDMR | 11.441599
| 12,909 (of which 4,794 were sold and 8,115 retained) | N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
ii. FINAL VESTING OF 2022 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2022 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Final vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9 March 2022 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date of Transaction | 9 March 2025 (vesting) and 10 March 2025 (market sale) |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information |
Helen Barraclough (Group General Counsel and Company Secretary) | PDMR | 11.441599
| 1,815 (of which 857 were sold and 958 retained) | N/A Single Transaction |
Phil Cowdy (Chief Corporate Development and Corporate Affairs Officer) | PDMR | 11.441599 | 2,976 (of which 1,404 were sold and 1,572 retained) | N/A Single Transaction |
Craig Gaffin (President, Global Orthopaedics) | PDMR | 11.441599 | 896 (of which 267 were sold and 629 retained) | N/A Single Transaction |
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) | PDMR | 11.441599 | 752 (of which 278 were sold and 474 retained) | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | 11.441599 | 4,247 (of which 1,690 were sold and 2,557 retained) | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development ENT) | PDMR | 11.441599 | 3,436 (of which 1,276 were sold and 2,160 retained) | N/A Single Transaction |
Scott Schaffner (President Sports Medicine) | PDMR | 11.441599 | 2,496 (of which 927 were sold and 1,569 retained) | N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
iii. PARTIAL VESTING OF 2023 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2023 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Partial vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9 March 2023 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date of Transaction | 9 March 2025 (vesting) and 10 March 2025 (market sale) |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information |
Helen Barraclough (Group General Counsel and Company Secretary) | PDMR | 11.441599 | 1,761 (of which 830 were sold and 931 retained) | N/A Single Transaction |
Paul Connolly (President, Global Operations) | PDMR | 11.441599 | 1,995 (of which 682 were sold and 1,313 retained) | N/A Single Transaction |
Phil Cowdy (Chief Corporate Development and Corporate Affairs Officer) | PDMR | 11.441599 | 1,897 (of which 895 were sold and 1,002 retained) | N/A Single Transaction |
Craig Gaffin (President, Global Orthopaedics) | PDMR | 11.441599 | 590 (of which 176 were sold and 414 retained) | N/A Single Transaction |
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) | PDMR | 11.441599 | 2,040 (of which 755 were sold and 1,285 retained) | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | 11.441599 | 2,985 (of which 1,187 were sold and 1,798 retained) | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development ENT) | PDMR | 11.441599 | 2,429 (of which 902 were sold and 1,527 retained) | N/A Single Transaction |
Alison Parkes (Chief Compliance Officer) | PDMR | 11.441599 | 1,055 (of which 476 were sold and 579 retained) | N/A Single Transaction |
Scott Schaffner (President Sports Medicine) | PDMR | 11.441599 | 975 (of which 362 were sold and 613 retained) | N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
iv. PARTIAL VESTING OF 2024 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 8 March 2024 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Partial vesting on 8 March 2025 of Deferred Bonus Share awards, granted on 8 March 2024 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date of Transaction | 8 March 2025 (vesting) and 10 March 2025 (market sale) |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information |
Helen Barraclough (Group General Counsel and Company Secretary) | PDMR | 11.441599 | 3,208 (of which 1,513 were sold and 1,695 retained.) | N/A Single Transaction |
Paul Connolly (President, Global Operations) | PDMR | 11.441599 | 3,373 (of which 1,153 were sold and 2,220 retained.) | N/A Single Transaction |
Phil Cowdy (Chief Corporate Development and Corporate Affairs Officer) | PDMR | 11.441599 | 3,456 (of which 1,630 were sold and 1,826 retained.) | N/A Single Transaction |
Craig Gaffin (President, Global Orthopaedics) | PDMR | 11.441599 | 1,908 (of which 567 were sold and 1,341 retained.) | N/A Single Transaction |
Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations) | PDMR | 11.441599 | 3,778 (of which 1,125 were sold and 2,653 retained) | N/A Single Transaction |
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) | PDMR | 11.441599 | 3,880 (of which 1,434 were sold and 2,446 retained.) | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | 11.441599 | 4,839 (of which 1,927 were sold and 2,912 retained.) | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development ENT) | PDMR | 11.441599 | 4,868 (of which 1,808 were sold and 3,060 retained.) | N/A Single Transaction |
Alison Parkes (Chief Compliance Officer) | PDMR | 11.441599 | 1,875 (of which 885 were sold and 990 retained.) | N/A Single Transaction |
Scott Schaffner (President Sports Medicine) | PDMR | 11.441599 | 6,046 (of which 2,245 were sold and 3,801 retained.) | N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
Philip Horner
Group Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
Follow the stocks
